Additional Resources Will Support Product Development and Expansion of Manufacturing Capabilities   Sacramento, Calif.—(May 19, 2020)—Nivagen Pharmaceuticals, Inc. (“Nivagen”), a specialty pharmaceuticals company, announced the

MADISON, WI–Nimble Therapeutics, Inc. today announced a collaboration with Roche Diagnostics to accelerate discovery of novel peptide-based molecules for the development of SARS-CoV-2 in vitro

MADISON, WI, USA and Malmö, SE — Nimble Therapeutics and Svar Life Science today announced a collaboration to discover, develop, and commercialize diagnostic tests based

Vancouver BC, April 8, 2020 Precision NanoSystems (PNI), a global leader in enabling transformative nanomedicines today announced the appointment of Dr. Andrew Geall as the

Funded by the Bill and Melinda Gates Foundation, CoVIC Seeks to Find Therapeutic Candidates for COVID-19 in Just Weeks Salt Lake City, Utah and La

Dynex’s portfolio of open, automated microplate instruments, with a global distribution network and footprint, demonstrates ability to support COVID-19 testing worldwide. CHANTILLY, VA March 27,

Vancouver BC, March 23, 2020  Precision Nanosystems, Inc. (PNI), a global leader in enabling transformative nanomedicines announced today that the company entered into a license

Advanced Facility Readies to Combat COVID-19 (Carlsbad, CA) March 23, 2020 – Argonaut Manufacturing Services announced today it has immediate availability for aseptic drug product

New reference material aims to facilitate and expedite global efforts to detect the novel coronavirus AUSTIN, Texas–(BUSINESS WIRE)– Asuragen, Inc. has developed an Armored RNA

Seattle, WA, February 27, 2020 – RareCyte announces a new liquid biopsy blood test for programmed death-ligand 1 (PD-L1), enabling customers to evaluate PD-L1 expression

Active Motif Shanghai (a subsidiary of Active Motif, Inc.), in collaboration with Fudan University and its affiliated Public Health Clinical Center, used its single-cell AbEpic™

The U.S. Food and Drug Administration today authorized marketing of the first test to detect a genetic condition known as Fragile X Syndrome (FXS), the